{"id":"https://openalex.org/W7202373180","doi":"https://doi.org/10.70322/imed.2026.10008","title":"The Residual Role of Doxorubicin\u2013Cisplatin in Endometrial Cancer in the TC Plus Immunotherapy Era","display_name":"The Residual Role of Doxorubicin\u2013Cisplatin in Endometrial Cancer in the TC Plus Immunotherapy Era","publication_year":2026,"publication_date":"2026-01-01","ids":{"openalex":"https://openalex.org/W7202373180","doi":"https://doi.org/10.70322/imed.2026.10008"},"language":"en","primary_location":{"id":"doi:10.70322/imed.2026.10008","doi":"https://doi.org/10.70322/imed.2026.10008","is_oa":true,"landing_page_url":"https://doi.org/10.70322/imed.2026.10008","pdf_url":"https://www.sciepublish.com/index/article/view_full_text/id/1167","source":{"id":"https://openalex.org/S5407056486","display_name":"iMed","issn_l":"3107-2976","issn":["3107-2976","3107-2984"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"iMed","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":true,"oa_status":"hybrid","oa_url":"https://www.sciepublish.com/index/article/view_full_text/id/1167","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5019037176","display_name":"Katsuaki Inami","orcid":"https://orcid.org/0009-0009-4260-3073","observed_orcids":["https://orcid.org/0009-0009-4260-3073"]},"institutions":[{"id":"https://openalex.org/I4405256185","display_name":"Fujinomiya City General Hospital","ror":"https://ror.org/03w0x6k04","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4405256185"]}],"countries":["JP"],"is_corresponding":true,"raw_author_name":"Inami Katsuaki","raw_affiliation_strings":["Department of Obstetrics and Gynecology , Fujinomiya City General Hospital , 3-1 Nishiki-cho , Fujinomiya-shi , Shizuoka 418-0076 , Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Obstetrics and Gynecology , Fujinomiya City General Hospital , 3-1 Nishiki-cho , Fujinomiya-shi , Shizuoka 418-0076 , Japan","institution_ids":["https://openalex.org/I4405256185"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5019037176"],"corresponding_institution_ids":["https://openalex.org/I4405256185"],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"1","issue":"1","first_page":"10008","last_page":"10008"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10668","display_name":"Endometrial and Cervical Cancer Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2729","display_name":"Obstetrics and Gynecology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10668","display_name":"Endometrial and Cervical Cancer Treatments","score":1.0,"subfield":{"id":"https://openalex.org/subfields/2729","display_name":"Obstetrics and Gynecology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10550","display_name":"Ovarian cancer diagnosis and treatment","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10183","display_name":"Breast Cancer Treatment Studies","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1306","display_name":"Cancer Research"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/endometrial-cancer","display_name":"endometrial cancer","score":0.9850000143051147},{"id":"https://openalex.org/keywords/carboplatin-paclitaxel","display_name":"carboplatin-paclitaxel","score":0.9539999961853027},{"id":"https://openalex.org/keywords/first-line-chemotherapy","display_name":"first-line chemotherapy","score":0.7020000219345093},{"id":"https://openalex.org/keywords/immunotherapy","display_name":"immunotherapy","score":0.6840000152587891},{"id":"https://openalex.org/keywords/molecular-classification","display_name":"molecular classification","score":0.5059999823570251},{"id":"https://openalex.org/keywords/pole-mutation","display_name":"POLE mutation","score":0.9229999780654907},{"id":"https://openalex.org/keywords/mismatch-repair-deficiency","display_name":"mismatch repair deficiency","score":0.9819999933242798},{"id":"https://openalex.org/keywords/p53","display_name":"p53","score":0.6859999895095825},{"id":"https://openalex.org/keywords/immune-checkpoint-blockade","display_name":"immune checkpoint blockade","score":0.7910000085830688},{"id":"https://openalex.org/keywords/parp-inhibition","display_name":"PARP inhibition","score":0.953000009059906},{"id":"https://openalex.org/keywords/treatment-selection","display_name":"treatment selection","score":0.3610000014305115}],"concepts":[{"id":"https://openalex.org/C2781451048","wikidata":"https://www.wikidata.org/wiki/Q415588","display_name":"Carboplatin","level":4,"score":0.7250999808311462},{"id":"https://openalex.org/C2781413609","wikidata":"https://www.wikidata.org/wiki/Q7308373","display_name":"Regimen","level":2,"score":0.717199981212616},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.6870999932289124},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.6603000164031982},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.60589998960495},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.5813999772071838},{"id":"https://openalex.org/C2778239845","wikidata":"https://www.wikidata.org/wiki/Q412415","display_name":"Cisplatin","level":3,"score":0.5803999900817871},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5354999899864197},{"id":"https://openalex.org/C2777292972","wikidata":"https://www.wikidata.org/wiki/Q423762","display_name":"Paclitaxel","level":3,"score":0.516700029373169},{"id":"https://openalex.org/C2777088508","wikidata":"https://www.wikidata.org/wiki/Q944777","display_name":"Endometrial cancer","level":3,"score":0.4880000054836273},{"id":"https://openalex.org/C2780851360","wikidata":"https://www.wikidata.org/wiki/Q21686041","display_name":"Immune checkpoint","level":4,"score":0.45419999957084656},{"id":"https://openalex.org/C2781303535","wikidata":"https://www.wikidata.org/wiki/Q18936","display_name":"Doxorubicin","level":3,"score":0.42750000953674316},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.41909998655319214},{"id":"https://openalex.org/C2777877232","wikidata":"https://www.wikidata.org/wiki/Q17144704","display_name":"Immunogenic cell death","level":4,"score":0.41440001130104065},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.3887999951839447},{"id":"https://openalex.org/C2779823535","wikidata":"https://www.wikidata.org/wiki/Q6865356","display_name":"Minimal residual disease","level":3,"score":0.3677000105381012},{"id":"https://openalex.org/C2778468042","wikidata":"https://www.wikidata.org/wiki/Q273976","display_name":"Blockade","level":3,"score":0.35010001063346863},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.3303999900817871},{"id":"https://openalex.org/C2778336483","wikidata":"https://www.wikidata.org/wiki/Q5090632","display_name":"Chemotherapy regimen","level":3,"score":0.29910001158714294},{"id":"https://openalex.org/C2780674031","wikidata":"https://www.wikidata.org/wiki/Q2012719","display_name":"Cancer immunotherapy","level":4,"score":0.2962999939918518},{"id":"https://openalex.org/C2780035454","wikidata":"https://www.wikidata.org/wiki/Q8386","display_name":"Drug","level":2,"score":0.28999999165534973},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.2623000144958496}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.70322/imed.2026.10008","doi":"https://doi.org/10.70322/imed.2026.10008","is_oa":true,"landing_page_url":"https://doi.org/10.70322/imed.2026.10008","pdf_url":"https://www.sciepublish.com/index/article/view_full_text/id/1167","source":{"id":"https://openalex.org/S5407056486","display_name":"iMed","issn_l":"3107-2976","issn":["3107-2976","3107-2984"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"iMed","raw_type":"journal-article"}],"best_oa_location":{"id":"doi:10.70322/imed.2026.10008","doi":"https://doi.org/10.70322/imed.2026.10008","is_oa":true,"landing_page_url":"https://doi.org/10.70322/imed.2026.10008","pdf_url":"https://www.sciepublish.com/index/article/view_full_text/id/1167","source":{"id":"https://openalex.org/S5407056486","display_name":"iMed","issn_l":"3107-2976","issn":["3107-2976","3107-2984"],"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"iMed","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":true,"grobid_xml":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7202373180.pdf","grobid_xml":"https://content.openalex.org/works/W7202373180.grobid-xml"},"referenced_works_count":19,"referenced_works":["https://openalex.org/W2041440766","https://openalex.org/W2098960933","https://openalex.org/W2120965358","https://openalex.org/W2169183724","https://openalex.org/W2925024852","https://openalex.org/W3093220519","https://openalex.org/W4360991857","https://openalex.org/W4360992337","https://openalex.org/W4365503784","https://openalex.org/W4381309093","https://openalex.org/W4387840851","https://openalex.org/W4399375060","https://openalex.org/W4399508081","https://openalex.org/W4404736942","https://openalex.org/W4406930216","https://openalex.org/W4407238737","https://openalex.org/W4408161023","https://openalex.org/W4412856013","https://openalex.org/W7140316177"],"related_works":["https://openalex.org/W2419613866","https://openalex.org/W2160061126","https://openalex.org/W4381614072","https://openalex.org/W4403775913","https://openalex.org/W2395815330","https://openalex.org/W2135987114","https://openalex.org/W2194011333","https://openalex.org/W2753978844","https://openalex.org/W2444340451","https://openalex.org/W2324373220"],"abstract_inverted_index":{"Doxorubicin":[0],"plus":[1,38],"cisplatin":[2,192],"(AP)":[3],"once":[4],"played":[5],"a":[6,25,67,209,221,226],"central":[7],"role":[8,229],"in":[9,146],"the":[10,45,59,76,85,90,103,118,132,170,185],"systemic":[11],"treatment":[12,133],"of":[13,62,80,96,105,187,191,196],"advanced":[14],"and":[15,19,111,124,139,148,179,194,205],"recurrent":[16],"endometrial":[17],"cancer":[18],"helped":[20],"establish":[21,208],"combination":[22],"chemotherapy":[23],"as":[24,44,58,220,230],"standard":[26],"approach":[27],"for":[28,48,172,213],"extra-uterine":[29],"disease.":[30],"Contemporary":[31],"practice,":[32],"however,":[33],"has":[34,129,155],"shifted":[35],"toward":[36],"carboplatin":[37],"paclitaxel":[39,106],"(TC),":[40],"which":[41],"now":[42],"serves":[43],"cytotoxic":[46],"backbone":[47],"first-line":[49,174],"immunotherapy-based":[50],"strategies.":[51],"This":[52],"transition":[53],"should":[54,216],"not":[55,207],"be":[56,218,240],"interpreted":[57],"simple":[60],"replacement":[61],"an":[63,94,231],"ineffective":[64],"regimen":[65,120,224],"by":[66],"definitively":[68],"superior":[69],"one.":[70],"No":[71],"dedicated":[72],"two-arm":[73],"trial":[74],"established":[75,100,235],"superiority":[77],"or":[78],"noninferiority":[79],"TC":[81,112,167],"over":[82],"AP":[83,98,108,163,215],"across":[84],"full":[86],"clinical":[87],"spectrum.":[88],"Rather,":[89],"change":[91],"resulted":[92],"from":[93,162],"accumulation":[95],"evidence:":[97],"had":[99],"historical":[101],"activity,":[102],"addition":[104],"to":[107,117,158],"improved":[109],"outcomes,":[110],"subsequently":[113],"achieved":[114],"similar":[115],"efficacy":[116],"three-drug":[119],"with":[121,200,225],"better":[122],"tolerability":[123],"practical":[125],"feasibility.":[126],"Molecular":[127],"classification":[128],"further":[130,183],"changed":[131],"landscape.":[134],"POLE-mutated,":[135],"mismatch":[136],"repair-deficient,":[137],"p53-abnormal,":[138],"no":[140,152],"specific":[141],"molecular":[142,153,211],"profile":[143],"tumors":[144],"differ":[145],"prognosis":[147],"therapeutic":[149],"relevance,":[150],"but":[151],"subgroup":[154],"been":[156],"shown":[157],"derive":[159],"preferential":[160],"benefit":[161],"rather":[164],"than":[165],"TC.":[166],"also":[168],"remains":[169],"platform":[171],"major":[173],"immunotherapy":[175],"trials,":[176],"whereas":[177],"biomarker-directed":[178],"later-line":[180],"options":[181],"have":[182],"reduced":[184],"competitiveness":[186],"AP.":[188,214],"Emerging":[189],"biomarkers":[190],"sensitivity":[193],"combinations":[195],"immune":[197],"checkpoint":[198],"blockade":[199],"PARP":[201],"inhibition":[202],"remain":[203],"investigational":[204],"do":[206],"new":[210],"niche":[212],"therefore":[217],"regarded":[219],"historically":[222],"important":[223],"narrow":[227],"residual":[228],"exceptional":[232],"fallback":[233],"when":[234],"contemporary":[236],"strategies":[237],"cannot":[238],"reasonably":[239],"used.":[241]},"counts_by_year":[],"updated_date":"2026-11-12T12:28:57.059296","created_date":"2026-08-14T00:00:00"}